|
May 12
|
Need To Know: Analysts Are Much More Bullish On Repare Therapeutics Inc. (NASDAQ:RPTX)
|
|
May 9
|
Repare Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 7
|
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
|
|
Apr 30
|
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
|
|
Apr 30
|
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
|
|
Apr 26
|
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
|
|
Apr 20
|
Repare Therapeutics Inc.'s (NASDAQ:RPTX) market cap dropped US$21m last week; Private equity firms bore the brunt
|
|
Dec 29
|
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
|
|
Aug 9
|
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 9
|
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
|
|
Aug 5
|
10 Oversold Canadian Stocks To Buy
|
|
Apr 28
|
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
|